Share on LinkedInShare on LinkedIn

ARTICLE · 13 JUNE 2017

Overhaul To Drug Pricing Regime Proposed In Canada

Torys
Torys
Contributor
Torys

Torys

Torys LLP is an international business law firm that works with clients who expect the best advice...

View firm profile
Explore more from Torys

The Patented Medicine Prices Review Board published the consultation paper "Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations."

CanadaIntellectual Property

On May 16, the Patented Medicine Prices Review Board (PMRPB) published the consultation paper "Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations." The PMPRB is seeking feedback on its proposal to amend the Patented Medicines Regulations under the Patent Act, with the underlying purpose to equip "the PMPRB with more relevant and effective regulatory tools to better protect Canadians from excessive prices for patented drugs."

What You Need To Know

Background

The proposal followed Health Minister Philpott's announcement on May 16, 2017 where she declared the government's goal of lowering "unacceptably high drug costs." The proposal is unlikely to be a surprise to stakeholders, as the PMPRB sought input on how to modernize pricing rules through its Rethinking the Guidelines consultation in 2016, which included many of the same themes as the proposal. It appears that after receiving feedback from

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from